BioCentury on BioBusiness, Finance
Regulatory, clinical and other milestones
Highlights of weekly biotech stock moves
Published on Monday, January 16, 2012
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $0.77 to $11.79 last week after
the U.K.'s NICE issued a final appraisal determination backing use of
once-weekly Bydureon exenatide to treat Type II diabetes in triple and dual
therapy regimens. The FAD is in line with a preliminary appraisal issued last
October. Bydureon uses drug delivery technology from Alkermes plc
(NASDAQ:ALKS), which was up $1.48 to $18.16 last week.
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $0.03 to $1.65 last week after
FDA accepted for review a resubmitted NDA for lorcaserin to treat obesity. The
PDUFA date is June 27.
95 words displayed of 993 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]